IPO Details
Bidding Dates
11 Dec 24 - 13 Dec 24
Price Range ₹
522 - 549
Total Equity
₹ 2131.76Cr
Lot Size
27
Exchange Status
NSE,BSE
IPO Doc
Subscription Rate
Non-Institutional Investor
1.37×
Qualified Institutional Buyers
30.93×
Employees
0.00×
Retail Investors
1.37×
Total subscription Rate
10.26×
IPO Timeline
Offer start
11 Dec 2024
Offer end
13 Dec 2024
Allotment
16 Dec 2024
Refund initiation
17 Dec 2024
Demat transfer
17 Dec 2024
Listing
18 Dec 2024
Offer start
11 Dec 2024
Offer end
13 Dec 2024
Allotment
16 Dec 2024
Refund initiation
17 Dec 2024
Demat transfer
17 Dec 2024
Listing
18 Dec 2024
About Company
Incorporated in January 1999, Sai Life Sciences Limited specializes in researching, developing, and manufacturing small-molecule new chemical entities. The company offers tailored services to biotech and global pharmaceutical firms, including over 280 innovator pharmaceutical companies, with more than 230 served in the month ending September 30, 2024. Among these clients, Sai Life Sciences collaborated with 18 of the top 25 pharmaceutical companies by revenue in 2023. The company operates across multiple regions, including the US, the UK, Europe, and Japan, with a skilled business development team of 16 professionals. Its service offerings include capabilities in chemistry, manufacturing, and control (CMC), contract development and manufacturing (CDMO), and integrated discovery services across biology, chemistry, drug metabolism, and pharmacokinetics. As of September 2024, Sai Life Sciences employed 3,135 staff, with 2,353 scientific personnel, including 302 Ph.D.s and 1,475 master’s degree holders. The company's competitive strength lies in its integrated CRDMO platform, offering a comprehensive approach to discovery, development, and manufacturing with a diverse mix of commercial and under-development molecules.
Year Founded
25-01-1999
Promotor Details
Kanumuri Ranga Raju
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 40.48 | 35.24 |
| Share Capital | 77704340 | 73293890 |
Offer to Public
3,88,29,848.00 Cr
Project Details
- Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by our Comp - 6000cr
Objectives
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company
- andGeneral corporate purposes.
Highlights
- Offers end-to-end CRAMS solutions, covering everything from drug discovery to commercial manufacturing.
- Serves a diverse international clientele, reducing reliance on any single region.
- Boasts state-of-the-art infrastructure and robust R&D capabilities.
- Demonstrates strong financial performance with consistent growth in revenue, profits, and operational efficiency.
- Led by experienced industry veterans who are driving strategic growth and market positioning.
Challenges
- High revenue concentration from key clients creates dependency risks.
- Faces intense competition from both global and regional CRAMS players.
- Strict global regulatory norms can impact operations and compliance requirements.
- Sensitive to global economic conditions, which may influence outsourcing trends.
- Fluctuating input costs may put pressure on profitability and margins.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2021 | 1,81,741.98 | 1,781.65 | 7,632.53 | 7,632.53 | 4.6588 |
| 2023 | 21,785.86 | 180.10 | 12,84,56,776.00 | 12,84,56,776.00 | 0.9775 |
| 2020 | 1,41,038.00 | 1,638.29 | 4,760.30 | 4,760.30 | 3.4052 |
| 2024 | 22,620.03 | 180.50 | 62.26 | 62.26 | 0.3546 |
| 2022 | 21,585.24 | 179.43 | 7,348.79 | 7,348.79 | 4.4901 |
